Publication:
Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study

Simple item page
dc.contributor.authorJara, Alejandro
dc.contributor.authorUndurraga, Eduardo
dc.contributor.authorFlores, Juan
dc.contributor.authorZubizarreta, José
dc.contributor.authorGonzález, Cecilia
dc.contributor.authorPizarro, Alejandra
dc.contributor.authorOrtuño, Duniel
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorLeo, Katherinne
dc.contributor.authorParedes, Fabio
dc.contributor.authorBralic , Tomás
dc.contributor.authorVergara, Verónica
dc.contributor.authorLeon, Francisco
dc.contributor.authorParot, Ignacio
dc.contributor.authorLeighton, Paulina
dc.contributor.authorSuárez, Pamela
dc.contributor.authorRios, Juan
dc.contributor.authorGarcía, Heriberto
dc.contributor.authorRafael Araos
dc.contributor.authorAraos Bralic, Rafael Ignacio
dc.date.accessioned2024-04-01T19:55:53Z
dc.date.available2024-04-01T19:55:53Z
dc.date.issued2023
dc.description.abstractBackground: Policymakers urgently need evidence to adequately balance the costs and benefits of mass vaccination against COVID-19 across all age groups, including children and adolescents. In this study, we aim to assess the effectiveness of CoronaVac's primary series among children and adolescents in Chile. Methods: We used a large prospective national cohort of about two million children and adolescents 6-16 years to estimate the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in preventing laboratory-confirmed symptomatic SARS-CoV-2 infection (COVID-19), hospitalisation, and admission to an intensive care unit (ICU) associated with COVID-19. We compared the risk of individuals treated with a complete primary immunization schedule (two doses, 28 days apart) with the risk of unvaccinated individuals during the follow-up period. The study was conducted in Chile from June 27, 2021, to January 12, 2022, when the SARS-CoV-2 Delta variant was predominant but other variants of concern were co-circulating, including Omicron. We used inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization over the unvaccinated status, accounting for time-varying vaccination exposure and adjusting for relevant demographic, socioeconomic, and clinical confounders. Findings: The estimated adjusted vaccine effectiveness for the inactivated SARS-CoV-2 vaccine in children aged 6-16 years was 74.5% (95% CI, 73.8-75.2), 91.0% (95% CI, 87.8-93.4), 93.8% (95% CI, 87.8-93.4) for the prevention of COVID-19, hospitalisation, and ICU admission, respectively. For the subgroup of children 6-11 years, the vaccine effectiveness was 75.8% (95% CI, 74.7-76.8) for the prevention of COVID-19 and 77.9% (95% CI, 61.5-87.3) for the prevention of hospitalisation. Interpretation: Our results suggest that a complete primary immunization schedule with the inactivated SARS-CoV-2 vaccine provides effective protection against severe COVID-19 disease for children 6-16 years. Funding: Agencia Nacional de Investigación y Desarrollo (ANID) Millennium Science Initiative Program and Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias (FONDAP)
dc.description.versionPublicada
dc.identifier.citationJara A, Undurraga EA, Flores JC, Zubizarreta JR, González C, Pizarro A, Ortuño-Borroto D, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V, Leon F, Parot I, Leighton P, Suárez P, Rios JC, García-Escorza H, Araos R. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. Lancet Reg Health Am. 2023 May;21:100487. doi: 10.1016/j.lana.2023.100487
dc.identifier.doihttps://doi.org/10.1016/j.lana.2023.100487
dc.identifier.urihttps://hdl.handle.net/11447/8575
dc.language.isoen
dc.subjectCOVID-19
dc.subjectInactivated SARS-CoV-2 vaccine
dc.subjectPaediatric cohort
dc.subjectSARS-CoV-2
dc.subjectVaccine effectiveness
dc.subjectmRNA vaccine
dc.titleEffectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceLancet regional health. Americas
dspace.entity.typePublication
relation.isAuthorOfPublication525e6967-5802-4c1a-b67f-35abb11bf1f1
relation.isAuthorOfPublication69e40056-7a55-41b3-8a65-05aace0e07e3
relation.isAuthorOfPublication.latestForDiscovery525e6967-5802-4c1a-b67f-35abb11bf1f1

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents_ a large-scale observational study.pdf
Size:
359.7 KB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services